Back
Corporate News
GSK India’s revenue rose 15% to INR 924 crores in Q1 2026, PAT up 24%
03-Aug-2026, 05:32
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced a 15% year-over-year increase in revenue to INR 924 crores for the first quarter ended June 30, 2026, with Profit After Tax (PAT) rising 24% to INR 253 crores, according to a press release issued Tuesday. The company’s performance reflects continued progress in its portfolio transformation strategy, with key promoted brands like Augmentin and Zejula demonstrating strong growth, and the Oncology business led by Jemperli and Zejula significantly expanding patient reach, while GSK India is preparing for key pipeline launches including Blenrep and Arexvy.
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced a 15% year-over-year increase in revenue to INR 924 crores for the first quarter ended June 30, 2026, with Profit After Tax (PAT) rising 24% to INR 253 crores, according to a press release issued Tuesday. The company’s performance reflects continued progress in its portfolio transformation strategy, with key promoted brands like Augmentin and Zejula demonstrating strong growth, and the Oncology business led by Jemperli and Zejula significantly expanding patient reach, while GSK India is preparing for key pipeline launches including Blenrep and Arexvy.